Clinical Trials of Modification of Mortality During Acute Myocardial Infarction

  • William T. Friedewald
  • Curt D. Furberg


Approximately 675,000 patients are admitted annually with a diagnosis of myocardial infarction (MI) to hospitals in the United States. Of these patients, 12%–15% will die during the hospitalization if this is their first MI; for recurrent MIs the percentage is even higher. To lessen this mortality, numerous interventions have been proposed and many have been critically evaluated in randomized controlled clinical trials.


Acute Myocardial Infarction Total Mortality Thrombolytic Agent Myocardial Infarc Cardial Infarction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    May GS, Chir B, Furberg CD, Eberlein KA, Geraci BJ: Secondary prevention after myocardial infarction: a review of short-term acute phase trials. Prog Cardiovasc Dis 25: 335–359, 1983.PubMedCrossRefGoogle Scholar
  2. 2.
    Cornfield J: A statistical problem arising from retrospective studies: proceedings of the 3rd Berkeley symposium on mathematical statistics and probability. Berkeley: University of California Press, 1956.Google Scholar
  3. 3.
    Holmberg S, Bergman H: Prophylactic quinidine treatment in myocardial infarction: a double-blind study. Acta Med Scand 181: 297–304, 1967.PubMedCrossRefGoogle Scholar
  4. 4.
    Jones DT, Kostuk WJ, Gunton RW: Prophylactic quinidine for the prevention of arrhythmias after acute myocardial infarction. Am J Cardiol 33: 655–660, 1974.PubMedCrossRefGoogle Scholar
  5. 5.
    Reynell PC: Prophylactic procaine amide in myocardial infarction. Br Heart J 23: 421–424, 1961.PubMedCrossRefGoogle Scholar
  6. 6.
    Koch-Weser J, Klein SW, Foo-Canto LL, Kastor JA, De Sanctis RW: Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. N Engl J Med 281: 1253–1260, 1969.PubMedCrossRefGoogle Scholar
  7. 7.
    Jennings G, Model DG, Jones MBS, Turner PP, Besterman EMM, Kidner PH: Oraldisopyramide in prophylaxis of arrhythmias following myocardial infarction. Lancet 1: 51–54, 1976.PubMedCrossRefGoogle Scholar
  8. 8.
    Nicholls DP, Haybyrne T, Barnes PC: Intravenous and oral disopyramide after myocardial infarction. Lancet 2: 936–938, 1980.PubMedCrossRefGoogle Scholar
  9. 9.
    Wilcox RG, Rowley JM, Hampton JR, Mitchell JRA, Roland JM, Banks DC: Randomized placebo-controlled trial comparing Oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. Lancet 2: 765–769, 1980.PubMedCrossRefGoogle Scholar
  10. 10.
    Bennett MA, Wilner JM, Pentecost BL: Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet 2: 909–911, 1970.PubMedCrossRefGoogle Scholar
  11. 11.
    Pitt A, Lipp H, Anderson ST: Lignocaine given prophylactically to patients with acute myocardial infarction. Lancet 1: 612–616, 1971.PubMedCrossRefGoogle Scholar
  12. 12.
    Darby S, Bennett MA, Cruickshank JC, Pentecost BL: Trial of combined intramuscular and intravenous lignocaine in prophylaxis of ventricular tachyarrhythmias. Lancet 1: 817–819, 1972.PubMedCrossRefGoogle Scholar
  13. 13.
    O’Brien KP, Taylor PM, Croxson RS: Prophylactic lidocaine in hospitalized patients with acute myocardial infarction. Med J Aust (Suppl) 2: 36–37, 1973.Google Scholar
  14. 14.
    Lie KI, Wellens HJ, Van Capelle FJ, Dürrer D: Lidocaine in the prevention of primary ventricular fibrillation: a double-blind, randomized study of 212 consecutive patients. N Engl J Med 291: 1324–1326, 1974.PubMedCrossRefGoogle Scholar
  15. 15.
    Valentine PA, Frew JL, Mashford ML, Sloman JG: Lidocaine in the prevention of sudden death in the prehospital phase of acute infarction: a double-blind study. N Engl J Med 291: 1327–1331, 1974.PubMedCrossRefGoogle Scholar
  16. 16.
    Lie KI, Liem KL, Louridtz WJ, Janse MJ, Wille-brands AF, Durrer D: Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection: a double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. Am J Cardiol 42: 486–488, 1978.PubMedCrossRefGoogle Scholar
  17. 17.
    Campbell RWE, Achuff SC, Pottage AP, Murray A, Prescott LF, Julian DG: Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction. J Cardiovasc Pharmacol 1: 43–52, 1979.PubMedCrossRefGoogle Scholar
  18. 18.
    Gazes PC, Gaddy JE: Bedside management of acute myocardial infarction. Am Heart J 97: 782–796, 1979.PubMedCrossRefGoogle Scholar
  19. 19.
    Manson DI, Fuilerton HW: Anticoagulant therapy in cardiac infarction. BrMedJ 1: 6–8, 1956.Google Scholar
  20. 20.
    Carleton RA, Sanders CA, Burack WR: Heparin administration after acute myocardial infarction. N Engl J Med 263: 1002–1005, I960.Google Scholar
  21. 21.
    Assessment of short-term anticoagulant administration after cardiac infarction: report of working party on anticoagulant therapy in coronary thrombosis to the Medical Research Council. Br Med J 1:335–342, 1969.Google Scholar
  22. 22.
    Drapkin A, Merskey C: Anticoagulant therapy after acute myocardial infarction: relation of therapeutic benefit of patient’s age, sex, and severity of infarction. JAMA 222: 541–548, 1972.PubMedCrossRefGoogle Scholar
  23. 23.
    Results of a cooperative clinical trial: anticoagu-lants in acute myocardial infarction. JAMA 225: 724–729, 1973.Google Scholar
  24. 24.
    Wasserman A, Gutterman LA, Yoe KB, Kemp VE Jr, Richardson DW: Anticoagulants in acute myocardial infarction. Am Heart J 71: 43–49, 1966.PubMedCrossRefGoogle Scholar
  25. 25.
    Gent AE, Brook CGD, Foley TH, Miller TN: Dipyridamole: a controlled trial of its effect in acute myocardial infarction. Br Med J 4: 366–368, 1968.PubMedCrossRefGoogle Scholar
  26. 26.
    Elwood PC, Williams WO: A randomized con-trolled trial of aspirin in the prevention of early mortality in myocardial infarction. J R Coll Gen Pract 29: 413–416, 1979.PubMedGoogle Scholar
  27. 27.
    Packham MA, Mustard JF: Pharmacology of platelet-affecting drugs. Circulation (Suppl 5 ) 62: V26–40, 1980.Google Scholar
  28. 28.
    Frishman WH: Multifactor actions of beta- adrenergic blocking drugs in ischemic heart disease: current concepts. Circulation (Suppl 1) 67: 1–11–18, 1983.Google Scholar
  29. 29.
    Balcón R, Jewitt DE, Davies JPH, Oram S: A controlled trial of propranolol in acute myocardial infarction. Lancet 2: 917–919, 1966.CrossRefGoogle Scholar
  30. 30.
    Clausen J, Felsby M, Jorgensen FS, Nielsen BL, Roin J, Strange B: Absence of prophylactic effect of propranolol in myocardial infarction. Lancet 2: 920–924, 1966.PubMedCrossRefGoogle Scholar
  31. 31.
    A multicentre trial: propranolol in acute myocardial infarction. Lancet 2:1435–1437, 1965.Google Scholar
  32. 32.
    Barber JM, Murphy FM, Merrett JD: Clinical trial of propranolol in acute myocardial infarction. Ulster Med J 36: 127–130, 1967.PubMedGoogle Scholar
  33. 33.
    Norris RM, Caughey DE, Scott PJ: Trial of propranolol in acute myocardial infarction. Br Med J 2: 398–400, 1968.PubMedCrossRefGoogle Scholar
  34. 34.
    Briant RB, Norris RM: Alprenolol in acute myocardial infarction: double-blind trial. N Z Med J 71: 135–138, 1970.PubMedGoogle Scholar
  35. 35.
    Evemy KL, Pentecost BL: Intravenous and oral practolol in the acute stages of myocardial infarction. Eur J Cardiol 7: 391–398, 1978.PubMedGoogle Scholar
  36. 36.
    Wilcox RG, Roland JM, Banks DC, Hampton JR, Mitchell JRA: Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br Med J 1: 885888, 1980.Google Scholar
  37. 37.
    Yusuf S, Sleight P, Rossi P, Ramsdale D, Peto R, Furze L, Sterry H, Pearson M, Motwani R, Parish S, Gray R, Bennett D, Bray C: Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation (Suppl 1) 67: 1–32–41, 1983.Google Scholar
  38. 38.
    Hjalmarson A, Elmfeldt D, HerlitzJ, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wil-helmsson C: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 2: 823–827, 1981.PubMedCrossRefGoogle Scholar
  39. 39.
    Coronary Prevention Research Group: An early intervention secondary prevention study with oxprenolol following myocardial infarction. Eur Heart J 2: 389–393, 1981.Google Scholar
  40. 40.
    Andersen MP, Bechsgaard P, Frederiksen J, Hansen DA, Jurgensen HJ, Nielsen B, Pedersen F, Pedersen-Bjergaard O, Rasmussen SL: Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Lancet 2: 865–868, 1979.PubMedCrossRefGoogle Scholar
  41. 41.
    Barber JM, Boyle McC, Chaturvedi NC, Singh N, Walsh MJ: Practolol in acute myocardial infarction. Acta Med Scand (Suppl) 587: 213–219, 1975.Google Scholar
  42. 42.
    Mcllmoyle, Evans A, McBoyles D, Cran G, Barber JM, Elwood H, Salathia K, Shanks R: Early intervention in myocardial ischemia: proceedings of the British Cardiac Society. Br Heart J 47: 188, 1982.CrossRefGoogle Scholar
  43. 43.
    Brogden RN, Speight TM, Avery GS: Streptoki-nase: a review of its clinical pharmacology, mech-anism of action and therapeutic uses. Drugs 5: 357–445, 1973.PubMedCrossRefGoogle Scholar
  44. 44.
    Amery A, Roeber G, Vermeulen HJ, Verstraete M: Single-blind randomised multicentre trial comparing heparin and streptokinase treatment in recent myocardial infarction. Acta Med Scand (Suppl) 505: 3–33, 1969.Google Scholar
  45. 45.
    European Working Party: Streptokinase in recent myocardial infarction: a controlled multicentre trial. Br Med J 3: 325–331, 1971.CrossRefGoogle Scholar
  46. 46.
    Heikinheimo R, Ahrenberg P, Honkapohja H, lisalo E, Kallio V, Konttinen Y, Leskinen O, Mustaniemi H, Reinikainene M, Siitonen L: Fibrinolytic treatment in acute myocardial infarction. Acta Med Scand 189: 7–13, 1971.PubMedCrossRefGoogle Scholar
  47. 47.
    Dioguardi N, Mannucci PM, Lotto A, Rossi P, Levi GF, Lomanto B, Rota M, Mattei G, Proto C, Fiorelli G, Agostoni A: Controlled trial of streptokinase and heparin in acute myocardial infarction. Lancet 2: 891–895, 1971.PubMedCrossRefGoogle Scholar
  48. 48.
    Breddin K, Ehrly AM, Fechler L, Frick D, Koenig H, Kraft H, Krause H, Krzywanek HJ, Kutschera J. Loesch HW, Ludwig O, Mikat B, Rausch F, Rosenthal P, Sartory S, Voigt G, Wylicil P: Die Kurzzeitfibrinolyse beim akuten Myokardinfarkt. Dtsch Med Wochenschr 98: 861–873, 1973.PubMedCrossRefGoogle Scholar
  49. 49.
    Brochier M, Raynaud R, Planiol T, Fauchier JP, Griguer P, Archambaud D, Pellios A, Clisson M: Le traitement par l’urokinase des infarctus du myocarde et syndromes de menace. Arch Mal Coeur 68: 563–569, 1975.PubMedGoogle Scholar
  50. 50.
    Bett HN, Biggs JC, Castaldi A, Chesterman CN, Haie GS, Hirsch J, Isbister JP, McDonald IG, McLean KH, Morgan JJ, O’Sullivan EF, Rosenbaum M: Australian multicentre trial of streptokinase in acute myocardial infarction. Lancet 1: 57–60, 1973.PubMedCrossRefGoogle Scholar
  51. 51.
    Ness PM, Simon TL, Cole C, Walston A: A pilot study of streptokinase therapy in acute myocardial infarction: observations on complications and relation to trial design. Am Heart J 88: 705–712, 1974.PubMedCrossRefGoogle Scholar
  52. 52.
    A European Collaborative Study: Controlled trial of urokinase in myocardial infarction. Lancet 2: 624–626, 1975.Google Scholar
  53. 53.
    Aber CP, Bass NM, Berry CL, Carson PHM, Dobbs RJ, Fox KM, Hamblin JJ, Haydu SP, Howitt G, Maclver JE, Portal RW, Raftery EB, Rousell RH, Stock JPP: Streptokinase in acute myocardial infarction: a controlled multcentre study in the United Kingdom. Br Med J 2: 1100–1104, 1976.PubMedCrossRefGoogle Scholar
  54. 54.
    Poliwoda H, Schneider B, Avenarius HJ: Unter-suchungen zum klinischen Verlauf des akuten Myokardinfarktes. Gemeinschaftsstudie an 26 krankenhaeusern in Norddeutschland. Teil 1: Die fibrinolytische Therapie des Myodarkinfarktes mit Streptokinase. Med Klin 72: 451–458, 1977.PubMedGoogle Scholar
  55. 55.
    Benda L, Haider M, Ambrosch F: Ergebnisse der oesterreichischen Herzinfarktstudie mit Streptokinase. Wiener Klin Wochenshr 89: 779–783, 1977.Google Scholar
  56. 56.
    European Cooperative Study Group: Streptokinase in acute myocardial infarction. N Engl J Med 301: 797–802, 1979.CrossRefGoogle Scholar
  57. 57.
    Furberg CD: Clinical value of intracoronary streptokinase. Am J Cardiol 53: 626–627, 1984.PubMedCrossRefGoogle Scholar
  58. 58.
    Mittra B: Potassium, glucose, and insulin in treatment of myocardial infarction. Lancet 2: 607–609, 1965.PubMedCrossRefGoogle Scholar
  59. 59.
    Pentecost BL, Mayne NMC, Lamb P: Controlled trial of intravenous glucose, potassium, and insulin in acute myocardial infarction. Lancet 1: 946–948, 1968.PubMedCrossRefGoogle Scholar
  60. 60.
    Medical Research Council Working-Party on the Treatment of Myocardial Infarction: Potassium, glucose, and insulin treatment for acute myocardial infarction. Lancet 2: 1355–1360, 1968.Google Scholar
  61. 61.
    Maroko PR, Hillis LD, Muller JE, Tavazzi L, Heyndrickx GR, Ray M, Chiariello M, Distante A, Askenazi J, Salerno J, Carpentier J, Reshetnaya NI, Radvany P, Libby P, Raabe DS: Favorable effects of hyaluronidase on electrocardiographic evidence of necrosis in patients with acute myocardial infarction. N Engl J Med 296: 898–903, 1977.PubMedCrossRefGoogle Scholar
  62. 62.
    Flint EJ, Cadigan PJ, DeGiovanni J, et al: Effect of GL enzyme (a highly purified form of hyaluronidase) on mortality after myocardial infarction. Lancet 1: 871–874, 1982.PubMedCrossRefGoogle Scholar
  63. 63.
    Henderson A, Campbell RWE, Julian DG: Effect of a highly purified hyaluronidase preparation (GL enzyme) on electrocardiographic changes in acute myocardial infarction. Lancet 1: 874–876, 1982.PubMedCrossRefGoogle Scholar
  64. 64.
    Flaherty JT, Becker LC, Weisfeldt ML, Weiss JL, Gerstenblith G, Kallman CH, Bulkley BH: Results of a prospective randomized clinical trial of intravenous nitroglycerin in acute myocardial infarction. Circulation 62: 111–82, 1980.Google Scholar
  65. 65.
    Durrer JD, Lie KI, Van Capelle FJL, et al: Effect of sodium nitroprusside on mortality in acute myocardial infarction. N Engl J Med 306: 1121–1128, 1982.PubMedCrossRefGoogle Scholar
  66. 66.
    Cohn JN, Franciosa JA, Francis GS, et al: Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure. N Engl J Med 306: 1129–1135, 1982.PubMedCrossRefGoogle Scholar
  67. 67.
    Frishman WH, Furberg CD, Friedewald WT: B-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 310: 830–837, 1984.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston/Dordrecht/Lancaster 1985

Authors and Affiliations

  • William T. Friedewald
  • Curt D. Furberg

There are no affiliations available

Personalised recommendations